Lasika C. Seneviratne
Expertise in
37
conditions

Dr. Lasika C. Seneviratne

Internal Medicine
222 W Eulalia St, 
Glendale, CA 
On Staff At
Offers Telehealth
34 Years of Experience
Expertise in
37
conditions
222 W Eulalia St, 
Glendale, CA 

Overview

The mission of The Los Angeles Cancer Network is to provide compassionate individualized treatment using the most recent proven advances in cancer care as well as education and support to our patients and their families.

Dr. Seneviratne is highly rated in 37 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Agranulocytosis, and Inflammatory Breast Cancer.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Colombo , 1992 , Colombo 8, 1992

Residency

LAC-USC Medical Center , Internal Medicine , 1996 - 1998

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

LAC-USC Medical Center , Hematology & Oncology , 1998 - 2001

Hospital Affiliations

California Hospital Medical Center
Glendale Memorial Hospital And Health Center
Northridge Hospital Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Los Angeles Hematology
222 W Eulalia St, Glendale, CA 91204
Other Locations
Oncology Physicians Network Of California Pc
1936 Huntington Dr, South Pasadena, CA 91030
Los Angeles Hematology
1245 Wilshire Blvd, Los Angeles, CA 90017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study
Enrollment Status: Completed
Publish Date: June 08, 2022
Intervention Type: Procedure
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine

Cancer Center Of Southern California

2811 Wilshire Blvd, 
Santa Monica, CA 
 (12.1 miles away)
310-552-9999
Experience:
51+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is an Internal Medicine provider in Santa Monica, California. Dr. Chawla has been practicing medicine for over 51 years is highly rated in 29 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Expertise in
16
conditions
Dr. Charles Bernstein
Internal Medicine
Expertise in
16
conditions
Dr. Charles Bernstein
Internal Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (10.4 miles away)
310-794-9718
Languages Spoken:
English

Charles Bernstein is an Internal Medicine provider in Los Angeles, California. Dr. Bernstein is highly rated in 16 conditions, according to our data. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

Expertise in
19
conditions
Dr. Myron Tong
Internal Medicine
Expertise in
19
conditions
Dr. Myron Tong
Internal Medicine

Office

625 S Fair Oaks Ave Ste 400 Lbby, 
Pasadena, CA 
 (8.2 miles away)
626-568-1622
Languages Spoken:
English
See accepted insurances

Myron Tong is an Internal Medicine provider in Pasadena, California. Dr. Tong is highly rated in 19 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Fibrolamellar Carcinoma, and Liver Transplant.

Frequently Asked Questions about Dr. Lasika C. Seneviratne

How do I make an appointment with Dr. Lasika C. Seneviratne?

You can book an appointment with Dr. Lasika C. Seneviratne by calling their office at 818-553-8160. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lasika C. Seneviratne a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lasika C. Seneviratne is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lasika C. Seneviratne specialize in?

While Dr. Lasika C. Seneviratne is a Internal Medicine, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Lasika C. Seneviratne accept my insurance?

Dr. Lasika C. Seneviratne accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 818-553-8160 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Seneviratne's expertise for a condition
ConditionClose
    View All 33 Advanced Conditions
    View All 143 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile